article thumbnail

Opinion: Secrecy: A demon of gene therapy’s past bedevils its future

STAT News

Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough treatments. Then it was almost instantly derailed by the death of an 18-year-old clinical trial volunteer named Jesse Gelsinger after he received a genetically engineered virus that had been developed to treat his rare liver condition.

Gene 111
article thumbnail

AGC and RoosterBio partner for cell and exosome therapy manufacturing

Pharmaceutical Technology

Biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics has entered a strategic collaboration with RoosterBio to expedite the manufacturing of cell and exosome therapies. These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But while companies continue studying allogeneic CAR-T therapies, including for their coveted use in solid tumours, such advancements remain challenging. More broadly however, several advancements are on the horizon for cell and gene therapies in 2023. AZ: Cell and gene therapies often come with a high price.

article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

The next wave of medicine is well on course to be cell and gene-based. In September 2021, GlobalData figures revealed there to be 1,320 industry-sponsored regenerative medicine and advanced therapy trials ongoing worldwide. In the evolving biotechnology industry, enzymes are important process aids.

Drugs 295
article thumbnail

Researchers Halt Trial of Promising Sickle Cell Treatment

NY Times

Two patients in a gene therapy study developed cancer years after treatment. It is not clear whether the therapy was responsible.

article thumbnail

Risk Assessment for use of Engineered Genetic Materials in Clinical Research

Advarra

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Either way, occupational exposure to these gene delivery systems bears potential risks to the research staff.

article thumbnail

mRNA Cancer Vaccines and Therapies: An Overview

Advarra

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.